This Article Full Text Full Text (PDF) All Versions of this Article: 34/10/2415    most recent 01.STR.0000092124.52084.4Bv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McQuillan, A. M. Articles by Cole, V. Search for Related Content PubMed PubMed Citation Articles by McQuillan, A. M. Articles by Cole, V. Related Collections Coagulation Thrombosis risk factors Acute Cerebral Infarction Risk Factors for Stroke

(Stroke. 2003;34:2415.)
© 2003 American Heart Association, Inc.

Original Contributions

Protein Z in Ischemic Stroke and its Etiologic Subtypes

Andrew M. McQuillan, MBBS; John W. Eikelboom, MBBS; Graeme J. Hankey, MBBS; Ross Baker, MBBS; Jim Thom, BSc; Janelle Staton, PhD; Qilong Yi, PhD Vanessa Cole, BSc

From the Department of Hematology (A.M.M., J.W.E., R.B., J.T., J.S., V.C.) and Stroke Unit, Department of Neurology (J.W.E., G.J.H.), Royal Perth Hospital, Perth, Australia; School of Medicine and Pharmacology, University of Western Australia, Perth, Australia (J.W.E., G.J.H., R.B.); and Biostatistics Department, Princess Margaret Hospital, Toronto, Canada (Q.Y.).

Reprint requests to John Eikelboom, Department of Hematology, Royal Perth Hospital, Box X2213 GPO, Perth WA 6897, Australia. E-mail john.eikelboom{at}health.wa.gov.au

Background and Purpose— Protein Z is a vitamin K–dependent plasma protein whose significance in arterial thrombosis remains uncertain. The objectives of this study were to determine the association between protein Z, ischemic stroke, and etiologic subtypes of ischemic stroke.

Methods— We conducted a case-control study of 173 hospital cases of first-ever ischemic stroke and 186 randomly selected community controls. Using established criteria, we classified cases of stroke by etiologic subtype. Protein Z concentrations were measured during the first 7 days and at 3 to 6 months after the acute stroke event.

Results— Blood levels of protein Z measured within 7 days of acute stroke were significantly higher in cases than in controls (geometric mean, 1.46 versus 1.16 µg/mL; P<0.0001). Compared with the lowest tertile, the upper 2 tertiles of protein Z were associated with an adjusted odds ratio (OR) of ischemic stroke of 1.75 (95% CI, 1.00 to 3.07) for the second tertile and 3.07 (95% CI, 1.73 to 5.45) for the upper tertile. The adjusted odds of ischemic stroke caused by large-artery atherothrombosis was nearly 8-fold greater for those with protein Z concentrations in the upper tertile compared with the lower tertile (OR, 7.91; 95% CI, 3.11 to 20.14). The adjusted odds of ischemic stroke due to small-artery disease (OR, 1.79; 95% CI, 0.83 to 3.87) and cardioembolism (OR, 1.80; 95% CI, 0.58 to 5.64) was also increased among individuals with protein Z concentrations in the upper tertile compared with the lower tertile, but not significantly so. There was no significant difference between mean protein Z concentrations among cases in the convalescent phase (3 months) after stroke and age- and sex-matched controls.

Conclusions— There is a strong, independent relationship between elevated blood levels of protein Z and ischemic stroke during the acute phase, particularly ischemic stroke due to large-artery atherothromboembolism, which is no longer evident during the convalescent phase. These results are consistent with the notion that protein Z is either an important factor in the pathogenesis of ischemic stroke due to large-artery atherothromboembolism or an acute phase reactant. Further studies are required to elucidate whether protein Z has a causative or prognostic role in acute arterial thrombosis.

Key Words: blood proteins • cerebrovascular accident • intracranial embolism • intracranial thrombosis • protein Z

This article has been cited by other articles:

				J. Zhang, Y. Tu, L. Lu, N. Lasky, and G. J. Broze Jr Protein Z-dependent protease inhibitor deficiency produces a more severe murine phenotype than protein Z deficiency Blood, May 15, 2008; 111(10): 4973 - 4978. [Abstract] [Full Text] [PDF]

				J M Staton, M S Sayer, G J Hankey, J Attia, A Thakkinstian, Q Yi, V J Cole, R Baker, and J W Eikelboom Association between phosphodiesterase 4D gene and ischaemic stroke. J. Neurol. Neurosurg. Psychiatry, September 1, 2006; 77(9): 1067 - 1069. [Abstract] [Full Text] [PDF]

				M. J. Heeb, K. M. Cabral, and L. Ruan Down-regulation of Factor IXa in the Factor Xase Complex by Protein Z-dependent Protease Inhibitor J. Biol. Chem., October 7, 2005; 280(40): 33819 - 33825. [Abstract] [Full Text] [PDF]

				F. Sofi, F. Cesari, G. F. Gensini, R. Abbate, S. Fedi, J. W. Eikelboom, J. Staton, and G. J. Hankey Protein Z Levels, Protein Z G79A Polymorphism, and Prothrombotic Conditions * Response: Stroke, September 1, 2005; 36(9): 1821 - 1822. [Full Text] [PDF]

				J. Staton, M. Sayer, G.J. Hankey, V. Cole, J. Thom, and J.W. Eikelboom Protein Z Gene Polymorphisms, Protein Z Concentrations, and Ischemic Stroke Stroke, June 1, 2005; 36(6): 1123 - 1127. [Abstract] [Full Text] [PDF]

				M. Bern Observations on Possible Effects of Daily Vitamin K Replacement, Especially Upon Warfarin Therapy JPEN J Parenter Enteral Nutr, November 1, 2004; 28(6): 388 - 398. [Abstract] [Full Text] [PDF]